by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing
Crohn’s disease: FORTIFY study (Risankizumab) This comprehensive study includes several sub-studies to evaluate various aspects of Risankizumab treatment, including maintenance therapy, long-term safety, and patient-reported outcomes. Open-label extensions...
by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing
Crohn’s disease: GRAVITI study (Guselkumab as subcutaneous therapy) This study examines the safety and efficacy of guselkumab as a subcutaneous (injected under the skin) therapy for people with Crohn’s...
by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing
Crohn’s disease: DUET-CD study (combination of guselkumab and golimumab) Similar to ulcerative colitis, this study tests the combination of the two drugs for Crohn’s disease and compares it with the single application. The aim is to determine which therapy...
by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing
Ulcerative colitis: DUET-UC study (combination of guselkumab and golimumab) This study examines the efficacy and safety of combining the two medications guselkumab and golimumab compared to using each medication individually. The study is aimed at patients with...
by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing
Ulcerative colitis: COMMAND Study (Risankizumab) This study focuses on the drug risankizumab. It examines various phases, including a 52-week maintenance phase and open-label extensions, to assess safety and efficacy in patients who have previously responded to...
by Pauline Lauterbach | Jan 19, 2026 | For participants, Ongoing
Ulcerative colitis: ABTECT Maintenance Study This study tests the long-term safety and efficacy of the drug ABX464, taken once daily as maintenance therapy. It is aimed at patients who have not responded to other treatments—both conventional and advanced...
